Global Animal Sedative Market Size

Animal Sedative Market Analysis

The Global Animal Sedative Market size is estimated at USD 226.15 million in 2024, and is expected to reach USD 299.79 million by 2029, growing at a CAGR of 5.80% during the forecast period (2024-2029).

The COVID-19 pandemic significantly impacted the animal sedative market during the initial wave since the veterinary hospital and pharmacy operations were reduced significantly due to several containment measures, such as lockdown and social distancing measures taken by governments across the world. For instance, as per the study published by Faunalytics in December 2022, to avoid disease transmission during the pandemic, around 70% of clinics in the United States and Canada closed their doors to the public, resulting in animals attending visits without their guardians. Also, as per the same source, clinics often ran out of essential supplies. 82% of clinics had pet food, medications, or personal protective equipment shortages. 56% ran out of at least one of those items entirely. Vaccines were in particularly short supply. However, as the pandemic restrictions were eased, the animal sedative market will likely witness growth in the coming years due to the rise in animal surgery cases and the increase in veterinary sedative product launches.

Moreover, the major factors responsible for the growth of the animal sedatives market include a rise in incidences of zoonotic diseases associated with surgical procedures, an increase in the pet population, and growing investment in veterinary product development activities. For instance, 70% of U.S. households, or about 90.5 million families, own a pet, according to the 2021-2022 National Pet Owners Survey conducted by the American Pet Products Association (APPA). Hence, the rise in the pet population indicates an increased concern for pet health. Hence, pet owners will likely invest in pet health care, driving market growth over the forecast period.

Research studies and developments to compare the efficacy of different veterinary sedative products are expected to drive market growth. For instance, as per the article published in December 2022 in Frontiers, a single dosage of romifidine or a combination of romifidine and lidocaine administered epidurally elicited mild to moderate drowsiness and full anti-nociception in the perineal and inguinal regions of donkeys. The technique is convenient for providing analgesia because it is simple, cost-effective, and does not require special or advanced instruments. Hence, such development regarding the utilization of veterinary sedatives is expected to drive market growth over the forecast period.

Additionally, strategic partnerships and product launches by the key players are expected to drive market growth. For instance, in September 2022, Zoetis acquired Jurox, a privately held animal health company that develops, manufactures, and markets a wide range of veterinary medicines for treating livestock and companion animals. Jurox's operations are based in Australia, with additional regional offices in New Zealand, the U.S., Canada, and the U.K. The acquisition of Jurox brings Zoetis a range of important products primed for greater global expansion; a valuable animal health portfolio, including Alfaxan, an anesthetic product for companion animals; and high-quality local R&D and manufacturing operations in Australia, Zoetis' fourth largest market based on revenue in 2021.

Thus, due to the rise in the animal population, an increase in strategic activities by the key players, and an increase in research studies demonstrating the efficacy of sedatives, the studied market is expected to witness notable growth over the forecast period. However, emerging adverse effects of animal sedative drugs, such as respiratory diseases, lowering blood pressure, cardiovascular collapse, etc., and stringent government regulations for sedatives are expected to restrain the market growth over the forecast period.